TITLE

Effective immunosuppressive therapy in a patient with primary pulmonary hypertension

AUTHOR(S)
Bellotto, F.; Chiavacci, P.; Laveder, F.; Angelini, A.; Thiene, G.; Marcolongo, R.
PUB. DATE
April 1999
SOURCE
Thorax;Apr1999, p372
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877072

 

Related Articles

  • Beta-blocker therapy in an infant with pulmonary hypertension. Buchhorn, R.; Hulpke-Wette, M.; Wessel, A.; Bürsch, J. // European Journal of Pediatrics;1999, Vol. 158 Issue 12, p1007 

    Discusses the use of beta-blocker therapy in an infant with pulmonary hypertension. Description of primary pulmonary hypertension; Hemodynamic and neurohormonal data of the patient; Effectiveness of the beta-blocker therapy in protecting the myocardium against toxic norepinephrine levels.

  • Continuous IV Therapy Can Be Managed By Patients. Boyd, Leslie // RN;Jul2000, Vol. 63 Issue 7, p16 

    Reports on the effectiveness of prostacyclin therapy delivered by continuous intravenous infusion for patients with advanced primary pulmonary hypertension. Administration of the drug; Side effects.

  • Sjögren's Syndrome.  // Current Medical Literature: Rheumatology;2012, Vol. 31 Issue 2, p48 

    The article offers information on several studies related to Sjögren;s syndrome. A study examines the effect of intensive immunosuppressive therapy on long-term prognosis of pulmonary hemodynamics in patients suffering from pulmonary arterial hypertension associated with connective tissue...

  • Treatment of Primary Pulmonary Hypertension with Nifedipine. Rubin, Lewis J.; Nicod, Pascal; Hillis, L. David; Firth, Brian G. // Annals of Internal Medicine;Oct83, Vol. 99 Issue 4, p433 

    Evaluates the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements. Information on primary pulmonary hypertension; Potent systemic vasodilator agents that have been reported to reduce pulmonary vascular resistance in some...

  • Prostacyclin and Primary Pulmonary Hypertension. Rich, Stuart // Annals of Internal Medicine;9/15/94, Vol. 121 Issue 6, p463 

    Editorial. Offers observations on the use of prostacyclin in patients with primary pulmonary hypertension. Limitations of prostacyclin; Views on research on the therapy.

  • Long-term echocardiographic follow-up of a patient with primary pulmonary hypertension receiving iloprost inhalations. Pettersen, Eirik; Morstøl, Torstein Holm; Vegsundvåg, Johnny Aage // European Journal of Echocardiography;2005, Vol. 6 Issue 1, p67 

    Iloprost inhalation has recently emerged as an alternative therapy for severe primary pulmonary hypertension. In the studies documenting the effect of iloprost inhalation therapy, hemodynamic variables have been measured invasively. We have followed a patient with primary pulmonary hypertension...

  • Vasodilators and Prostaglandin Inhibitors in Primary Pulmonary Hypertensions. Hermiller, James B.; Bambach, Dennis; Thompson, Michael J.; Huss, Patricia; Fontana, Mary E.; Magorien, Raymond D.; Unverferth, Donald V.; Leier, Carl V. // Annals of Internal Medicine;Oct82, Vol. 97 Issue 4, p480 

    Deals with a study which determined and compared the resting hemodynamic effects of various vasodilator agents and prostaglandin inhibitors in patients with primary pulmonary hypertension. Background on primary pulmonary hypertension; Patient population; Baseline hemodynamic data; Discussion...

  • Adverse Hemodynamic Effects of Phentolamine in Primary Pulmonary Hypertension. Cohen, Murray L.; Kronzon, Itzhak // Annals of Internal Medicine;Nov81, Vol. 95 Issue 5, p591 

    Deals with the adverse hemodynamic effects of phentolamine in primary pulmonary hypertension. Background on primary pulmonary hypertension; Primary action of phentolamine.

  • Pulmonary Hypertension from Chronic Pulmonary Thromboembolism. Rich, Stuart; Levitzky, Sidney; Brundage, Bruce H. // Annals of Internal Medicine;Mar88, Vol. 108 Issue 3, p425 

    Provides information on pulmonary hypertension from chronic pulmonary thromboembolism. Reason for the development of pulmonary hypertension; Thrombosis in pulmonary hypertension from chronic pulmonary thromboembolism; Assays of plasma fibrinolytic components in patients with primary pulmonary...

  • Recognition and Management of Pulmonary Hypertension. Wanstall, J.C.; Jeffery, T.K. // Drugs;Dec1998, Vol. 56 Issue 6, p989 

    Pulmonary hypertension (mean pulmonary arterial pressure >20mm Hg at rest or >30mm Hg during exercise) occurs (i) as primary pulmonary hypertension (no known underlying cause), (ii) as persistent pulmonary hypertension of the newborn or (iii) secondary to a variety of lung and cardiovascular...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics